The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.